Literature DB >> 31648650

Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.

Xylia Q Peters1, Thembeka H Malinga1, Clement Agoni1, Fisayo A Olotu1, Mahmoud E S Soliman1.   

Abstract

BACKGROUND: Tankyrases are known for their multifunctionalities within the poly(ADPribose) polymerases family and playing vital roles in various cellular processes which include the regulation of tumour suppressors. Tankyrases, which exist in two isoforms; Tankyrase 1 and 2, are highly homologous and an integral part of the Wnt β -catenin pathway that becomes overly dysregulated when hijacked by pro-carcinogenic machineries.
METHODS: In this review, we cover the distinct roles of the Tankyrase isoforms and their involvement in the disease pathogenesis. Also, we provide updates on experimentally and computationally derived antagonists of Tankyrase whilst highlighting the precedence of integrative computer-aided drug design methods towards the discovery of selective inhibitors.
RESULTS: Despite the high prospects embedded in the therapeutic targeting and blockade of Tankyrase isoforms, the inability of small molecule inhibitors to achieve selective targeting has remained a major setback, even until date. This explains numerous incessant drug design efforts geared towards the development of highly selective inhibitors of the respective Tankyrase isoforms since they mediate distinct aberrancies in disease progression. Therefore, considering the setbacks of conventional drug design methods, can computer-aided approaches actually save the day?
CONCLUSION: The implementation of computer-aided drug design techniques in Tankyrase research could help complement experimental methods and facilitate ligand/structure-based design and discovery of small molecule inhibitors with enhanced selectivity. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Tankyrase; cancer therapy; computer-aided drug design; inhibitors; selective targeting; structural homology.

Year:  2019        PMID: 31648650     DOI: 10.2174/1871520619666191019114321

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.

Authors:  Xylia Q Peters; Clement Agoni; Mahmoud E S Soliman
Journal:  Cell Biochem Biophys       Date:  2022-05-30       Impact factor: 2.989

2.  Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.

Authors:  Ruben G G Leenders; Shoshy Alam Brinch; Sven T Sowa; Enya Amundsen-Isaksen; Albert Galera-Prat; Sudarshan Murthy; Sjoerd Aertssen; Johannes N Smits; Piotr Nieczypor; Eddy Damen; Anita Wegert; Marc Nazaré; Lari Lehtiö; Jo Waaler; Stefan Krauss
Journal:  J Med Chem       Date:  2021-12-08       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.